Breaking News Instant updates and real-time market news.

CE

Celanese

$109.84

-1.17 (-1.05%)

, LLNW

Limelight Networks

$4.69

-0.04 (-0.85%)

19:04
07/19/18
07/19
19:04
07/19/18
19:04

On The Fly: After Hours Movers

UP AFTER EARNINGS: Celanese (CE) up 6.2%... Limelight Networks (LLNW) up 4.3%... Intuitive Surgical (ISRG) up 3.8%... Microsoft (MSFT) up 3.3%... Skyworks Solutions (SWKS) up 2.6%... Capital One (COF) up 2.1%... E*Trade (ETFC) up 0.2%. ALSO HIGHER: PTC Therapeutics (PTCT) up 7.8% after acquiring Agilis Bio... Redwood Trust (RWT) up 7.0% after entering S&P SmallCap 600 index... American Electric (AEP) up 1.5% after Goldman Sachs upgrade... WEC Energy Group (WEC) up 1.3% after Goldman Sachs upgrade. DOWN AFTER EARNINGS: Skechers (SKX) down 24.4%. ALSO LOWER: FTD Companies (FTD) down 15.9% after CEO resignation and review of strategic alternatives... Zynebra Pharma (ZYNE) down 18.4% after equity offering.

CE

Celanese

$109.84

-1.17 (-1.05%)

LLNW

Limelight Networks

$4.69

-0.04 (-0.85%)

ISRG

Intuitive Surgical

$521.30

-6.37 (-1.21%)

MSFT

Microsoft

$104.70

-0.38 (-0.36%)

SWKS

Skyworks

$102.46

0.41 (0.40%)

COF

Capital One

$95.32

-1.77 (-1.82%)

ETFC

E-Trade

$61.20

-1.94 (-3.07%)

PTCT

PTC Therapeutics

$36.61

1.59 (4.54%)

RWT

Redwood Trust

$16.64

0.135 (0.82%)

AEP

American Electric

$70.65

0.41 (0.58%)

WEC

WEC Energy

$65.23

0.51 (0.79%)

SKX

Skechers

$33.24

0.61 (1.87%)

FTD

FTD Companies

$4.52

0.06 (1.35%)

ZYNE

Zynerba

$10.40

0.24 (2.36%)

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 02

    Aug

  • 08

    Aug

  • 08

    Aug

  • 14

    Aug

  • 21

    Aug

  • 27

    Aug

  • 04

    Sep

  • 20

    Jul

CE Celanese
$109.84

-1.17 (-1.05%)

06/15/18
BMOC
06/15/18
NO CHANGE
Target $150
BMOC
Outperform
Celanese price target raised to $150 from $137 at BMO Capital
BMO Capital analyst John McNulty raised his price target on Celanese to $150 and kept his Outperform rating, saying the company's Acetic Acid prices continue their upward trajectory amid a tight supply/demand environment, while the capacity curbs by China also support the pricing dynamic. The analyst notes that risk-reward is solidly to the upside for the stock as prices have now risen 10-14% sequentially in Q2.
05/17/18
05/17/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the company's transformation should drive "sustainably better growth," which should yield a higher valuation premium. 2. Valero (VLO) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Benny Wong saying recent underinvestment in refining, slippages in capacity additions and overdone concerns on long-term demand have set the stage for refining to enter a "golden age" through 2020. 3. ManTech (MANT) upgraded to Outperform from Market Perform at Wells Fargo with analyst Edward Caso citing valuation. 4. Celanese (CE) upgraded to Buy from Neutral at UBS with analyst John Roberts saying he believes the shares are undervalued and investors do not appreciate the stability and growth in the acetyls chain and the long-term potential in Engineered Materials. 5. Canadian National (CNI) upgraded to Buy from Underperform at BofA/Merrill with analyst Ken Hoexter saying service and volume growth rebounded faster than expected and will only be aided by an improving economy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/17/18
UBSW
05/17/18
UPGRADE
Target $130
UBSW
Buy
Celanese upgraded to Buy at UBS
As reported previously, UBS analyst John Roberts upgraded Celanese to Buy from Neutral. The analyst believes the shares are undervalued and investors do not appreciate the stability and growth in the acetyls chain and the long-term potential in Engineered Materials. He said the company is on track to deliver earnings growth of greater than 10%, with the potential for upside from strategic optionality. Roberts raised his price target to $130 from $120 on Celanese shares.
06/18/18
JEFF
06/18/18
NO CHANGE
Target $138
JEFF
Buy
Celanese price target raised to $138 from $130 at Jefferies
Jefferies analyst Laurence Alexander raised his price target for Celanese to $138 and keeps a Buy rating on the shares. The analyst forecasts 18% annual earnings growth through 2021 and believes demand "remains healthy."
LLNW Limelight Networks
$4.69

-0.04 (-0.85%)

11/13/17
DADA
11/13/17
NO CHANGE
Target $7
DADA
Buy
Limelight Networks geared for larger content than Akamai, says DA Davidson
DA Davidson analyst Mark Kelleher compares the networking technology at Limelight Networks (LLNW) versus that of Akamai (AKAM), saying that because Limelight is more centrally organized across its 84 data centers, it can deliver information with less internet congestion. Kelleher notes that he recently discussed the contrast with Limelight CFO Sajid Malhotra, who explained that customers are willing to pay more for this type of content delivery relative to Akamai, which places its Content Delivery Network within the data centers of its ISP partners. While Akamai's CDN is more advantageous for smaller content like web pages, Kelleher says the rapid growth in video is quickly creating congestion problems for its network. The analyst has a Buy rating on Limelight Networks, nudging his price target to $7 from $6 based on the company's return to top-line growth, as well as improved operating margins, cash flow, and positive earnings.
04/16/18
OPCO
04/16/18
INITIATION
Target $6
OPCO
Outperform
Limelight Networks initiated with an Outperform at Oppenheimer
Oppenheimer initiated Limelight Networks with an Outperform and $6 price target.
04/04/18
RILY
04/04/18
NO CHANGE
Target $6
RILY
Buy
Limelight oversold on lawsuit settlement, says B. Riley FBR
B. Riley FBR analyst Sameet Sinha views the selloff yesterday in shares of Limelight Networks (LLNW) after the company settled its outstanding litigation with Akamai (AKAM) as an overreaction. While Limelight did not receive a windfall, its litigation expense will now decline, Sinha tells investors in a research note. The analyst keeps a Buy rating on the shares with a $6 price target. Limelight closed yesterday down 11% to $3.89.
10/19/17
COWN
10/19/17
NO CHANGE
Target $6
COWN
Outperform
Limelight Networks price target raised to $6 from $4 at Cowen
Cowen analyst Jonathan Charbonneau raised his price target on Limelight Networks to $6 from $4 following solid Q3 results. The analyst noted the company increased its guidance driven by another quarter of healthy demand with accelerating growth in OTT. He continues to see the stock as undervalued. Charbonneau reiterated his Outperform rating on Limelight Networks shares.
ISRG Intuitive Surgical
$521.30

-6.37 (-1.21%)

06/18/18
PIPR
06/18/18
NO CHANGE
Target $96
PIPR
Overweight
Piper continues to recommend Medtronic after management meeting
After meeting with management, Piper Jaffray analyst Matt O'Brien continues to recommend building positions in Medtronic (MDT). The analyst views management's 4% plus revenue outlook over the next several years as "readily achievable and likely conservative." Management noted that given the low penetration rates of surgery performed on robots, they did not see a reason to be aggressive on pricing of their system once they get it to market, O'Brien tells investors in a research note. He believes that is a positive comment for Intuitive Surgical (ISRG). The analyst keeps an Overweight rating on Medtronic with a $96 price target.
06/05/18
CANT
06/05/18
NO CHANGE
Target $510
CANT
Overweight
Medtronic robot delay 'clear positive' for Intuitive Surgical, says Cantor
Medtronic (MDT) today at its analyst meeting said it expects commercial launch of its surgical robot in fiscal 2020, which is roughly a year delay compared to the company's prior expectations, Cantor Fitzgerald analyst Craig Bijou tells investors in a research note partially titled "ISRG's Headstart Gets Bigger." The analyst views the revised timing of the commercial launch of Medtronic's robot as a "clear positive" for Intuitive Surgical (ISRG). With the commercial launches of the Medtronic and Johnson & Johnson (JNJ) robots at least 18 months away, Intuitive should continue to grow its global installed base, further advancing its global surgical robotics leadership position, Bijou writes. He reiterates his Overweight rating on the shares with a $510 price target. The stock in afternoon trading is up $8.46 to $486.39.
06/27/18
BERN
06/27/18
INITIATION
Target $560
BERN
Outperform
Intuitive Surgical initiated with an Outperform at Bernstein
Bernstein analyst Lee Hambright started Intuitive Surgical with an Outperform rating and $560 as he believes it is a sustainable growth story. The analyst sees multiple durable growth drivers, namely U.S. hernia adoption, "catch-up" penetration OUS, and a strong new product cycle.
05/31/18
PIPR
05/31/18
NO CHANGE
Target $460
PIPR
Neutral
Intuitive Surgical shares to get lift on new FDA clearance, says Piper Jaffray
Though most expected clearance, Intuitive Surgical shares tomorrow will likely get a lift from the FDA approval for da Vinci Sp for urological procedures, Piper Jaffray analyst Matt O'Brien tells investors in a research note. Given the large number of inpatient invasive procedures of this kind, this will be a meaningful platform in the coming years, O'Brien adds. He keeps a Neutral rating on Intuitive Surgical, however, saying expectations are already quite high for the company to beat numbers.
MSFT Microsoft
$104.70

-0.38 (-0.36%)

07/18/18
KEYB
07/18/18
NO CHANGE
Target $110
KEYB
Overweight
Cyclical tailwinds could help lift Microsoft growth, says KeyBanc
KeyBanc analyst Brent Bracelin reiterates an Overweight rating and $110 price target for Microsoft as he believes it could benefit in the 2H from the combination of secular and cyclical tailwinds. The analyst sees Microsoft delivering double-digit revenue growth for the fourth consecutive quarter driven by healthy fundamentals across all three major segments and 40% secular growth in commercial cloud. While investor sentiment is mixed on moderating Azure growth, Bracelin thinks it this is misplaced given usage-based Azure growth could remain in the triple digits.
07/17/18
BOFA
07/17/18
NO CHANGE
Target $130
BOFA
Buy
Microsoft price target raised to $130 from $123 at BofA/Merrill
BofA/Merrill analyst Kash Rangan raised his price target for Microsoft to $130 from $123 as he expects a Q4 beat on revenues/EPS. His channel checks continue to suggest that potential upside opportunities exist long-term. The analyst believes E5 adoption could accelerate by end of CY2018 as market awareness of value proposition improves, while adoption trends should continue to be strong as feature sets good enough for enterprise wide deployments. Dynamics 365 is also seeing strong midmarket pull, he contends. Additionally, Rangan thinks gaming is underappreciated, but Fortnite could still be a tailwind. He reiterates a Buy rating on the shares.
07/18/18
FBCO
07/18/18
NO CHANGE
Target $115
FBCO
Outperform
Credit Suisse remains positive on Microsoft heading into Q4 results
Credit Suisse analyst Brad Zelnick remains positive on Microsoft heading into Q4 results. The analyst highlights incremental U.S. dollar strength since the time of last guidance, but is constructive on fundamental business drivers. Zelnick expects continued momentum in commercial cloud, driven by Azure growth and Office 365 strength. He reiterates an Outperform rating and $115 price target on the shares.
07/18/18
SBSH
07/18/18
NO CHANGE
Target $300
SBSH
Buy
Nvidia can selloff near-term on graphics commentary, says Citi
Citi analyst Atif Malik says his recent supply chain checks indicate discrete graphics gaming demand is expected to remain sluggish thru the September quarter due to a "sharp decline" in mining related demand on falling cryptocurrency prices, channel distributors and partners waiting for Nvidia's (NVDA) new Turing gaming card launch in the October quarter, and weak gaming console sales at Microsoft (MSFT) offset by the Nintendo (NTDOY) Switch. The analyst lowered his July and October quarter estimates for Nvidia to bring them in-line with consensus. He thinks the stock can selloff in the near-term on weaker than expected graphics commentary from TSMC (TSM), who reports on July 19, and AMD (AMD), who reports on July 25. Malik, however, keeps a Buy rating on Nvidia with a $300 price target. He believes his long-term thesis on the shares remains intact.
SWKS Skyworks
$102.46

0.41 (0.40%)

06/21/18
LOOP
06/21/18
INITIATION
Target $130
LOOP
Buy
Skyworks initiated with a Buy at Loop Capital
Loop Capital analyst Cody Acree initiated Skyworks with a Buy rating and $130 price target, stating that he views it as one of the companies best positioned to capitalize on its leadership in the smartphone market.
06/15/18
BNCH
06/15/18
INITIATION
Target $114
BNCH
Buy
Skyworks initiated with a Buy at Benchmark
Benchmark started Skyworks with a Buy rating and $114 price target. The firm views the company as an "attractive cash flow engine" with balance sheet optionality.
06/12/18
KEYB
06/12/18
NO CHANGE
KEYB
Apple iPhone inventories normalize, Galaxy S9 continue to disappoint, says KeyBanc
KeyBanc analyst John Vinh says his latest carrier surveys indicate stable sell-through of Apple's (AAPL) iPhone 8/X, and in line with store expectations. Accordingly, days of inventory have normalized at about 5 DOI and are consistent with healthy levels seen in past cycles, he adds. Conversely, the analyst notes that sell-through of the Samsung's (SSNLF) GS9 continues to deteriorate, accompanied by an increase in DOI. However, he notes a significant reduction in absolute inventories. While GS9 gives him pause, stable sell-through, and normalized iPhone 8/X inventories leave him incrementally more constructive ahead of the 2H ramp of the new iPhone 9 cycle. Vihn recommends investors continue to own Broadcom (AVGO), Skyworks (SWKS), and Synaptics (SYNA).
07/12/18
LOOP
07/12/18
NO CHANGE
Target $130
LOOP
Buy
Skyworks to deliver 'stable, in-line' Q3 results, says Loop Capital
Loop Capital analyst Cody Acree kept his Buy rating and $130 price target on Skyworks ahead of its Q3 earnings next week, saying that with much of the industry's excess smartphone inventory cleared, the company is positioned to "deliver stable in-line Q3 results". The analyst also cites the benefits of stronger Skyworkds' Broad Markets boosted by WiFi, automotive, and Internet of Things industry demand. Acree further anticipates "at least modest upside" in its Q4 guidance to reflect the seasonal build cycle at Apple and its new low-band PAD win.
COF Capital One
$95.32

-1.77 (-1.82%)

07/13/18
SPHN
07/13/18
NO CHANGE
Target $100
SPHN
Overweight
Stephens says Walmart move to Capital One cards would be opportunity for TSYS
After Bloomberg reported yesterday that Walmart (WMT) is considering moving its private-label and or co-brand card portfolios to Capital One (COF) from incumbent Synchrony (SYF), Stephens analyst Brett Huff called the potential switch an possible opportunity for TSYS (TSS), which he notes is the card issuer processor for Capital One. He estimates this move, if it happens, could represent about a $15M revenue opportunity for TSYS. Huff keeps an Overweight rating and $100 price target on TSYS shares.
07/13/18
SUSQ
07/13/18
NO CHANGE
SUSQ
Susquehanna says Walmart card flip could be loss for First Data, win for TSYS
After Bloomberg reported yesterday that Capital One (COF) is bidding to issue Walmart's (WMT) private-label card and replace incumbent Synchrony (SYF), Susquehanna analyst James Friedman noted that TSYS (TSS) is used by Capitol One for its issuer processing, while First Data (FDC) processes for Synchrony. If TSYS were to win the issuer processing business of the Walmart cards via a successful Capital One bid, Friedman estimates it could represent revenue upside of $11M-$15M. The firm has Positive ratings on First Data, Synchrony and TSYS.
07/13/18
FBCO
07/13/18
NO CHANGE
Target $45
FBCO
Outperform
Synchrony 'unlikely' to lose Walmart contract, says Credit Suisse
Credit Suisse analyst Moshe Orenbuch said he believes Synchrony Financial (SYF) is likely to retain its credit card contract with Walmart (WMT) following a Bloomberg report that said Capital One (COF) is bidding for the portfolio. Orenbuch says this is "not an ideal partnership" for Capital One, because while it has been a long-time player in the nonprime card business, he feels it is "less likely" that it would be comfortable acquiring a large portfolio with potential significant nonprime component such as the Walmart portfolio, particularly when it did not underwrite the loans. Orenbuch says that if Synchrony does retain the contract, which is expected to expire in 2019, the company will most likely have to cede more economics to Walmart in terms of profit sharing.
07/13/18
BTIG
07/13/18
NO CHANGE
Target $44
BTIG
Buy
Synchrony may have 'upper hand' in Walmart credit card bidding, says BTIG
BTIG analyst Mark Palmer is keeping his Buy rating and $44 price target on Synchrony (SYF), noting the 5.3% decline in its stock price after media reports that Walmart (WMT) is considering shifting its credit card program to Capital One (COF). The analyst believes that Synchrony may still have the upper hand over Capital One because Walmart's objective to build out its digital wallet and mobile payment capabilities is better served by Synchrony's "understated solid experience helping retailers to develop their mobile capabilities" given its recent acquisition of GPShopper, which assists retailers in developing mobile apps. Palmer adds that given the risks and complexity around the transfer of a store-card program, Walmart should require a "very significant advantage", and it is more likely that it will renew its Synchony agreement at "somewhat less favorable terms for the issuer".
ETFC E-Trade
$61.20

-1.94 (-3.07%)

04/20/18
RHCO
04/20/18
NO CHANGE
Target $70
RHCO
Buy
E-Trade price target raised to $70 from $66 at SunTrust
SunTrust analyst Douglas Mewhirter raised his price target on E-Trade to $70 after the company's "strong" Q1 results showing better than expected revenues from accelerated investments along with better net interest margins and "another loan loss reserve reversal". Mewhirter also raised his FY18 EPS to $3.70 from $3.27 on higher net interest margin forecasts, adding that his new price target reflects unchanged 19-times multiple for expected FY18 earnings. The analyst keeps his Buy rating on E-Trade.
05/21/18
WELS
05/21/18
NO CHANGE
Target $73
WELS
Outperform
E-Trade price target raised to $73 from $67 at Wells Fargo
Wells Fargo analyst Christopher Harris raised his price target for E-Trade to $73 from $67 saying he remains bullish on the shares as he sees the current valuation as hardly stretched, consensus EPS as much too low and the operating environment as remaining constructive. The analyst reiterates an Outperform rating on the shares.
06/04/18
COMP
06/04/18
INITIATION
Target $72
COMP
Buy
E-Trade initiated with a Buy at Compass Point
Compass Point initiated E-Trade with a Buy and $72 price target.
05/31/18
UBSW
05/31/18
NO CHANGE
Target $73
UBSW
Buy
E-Trade price target raised to $73 from $67 at UBS
UBS analyst Brennan Hawkin raised his price target on E-Trade to $73 from $67 as he believes the stakes have been raised for a potential buyout. The analyst said the probability remains unclear but a deal with peers is probably most attractive, although he does not rule out a bank or broker. His increased price target reflects some takeout premium given the active bidding process, noted Hawkin, who reiterated his Buy rating on E-Trade shares.
PTCT PTC Therapeutics
$36.61

1.59 (4.54%)

06/20/18
LEHM
06/20/18
DOWNGRADE
Target $45
LEHM
Underweight
Ionis Pharmaceuticals downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Gena Wang downgraded Ionis Pharmaceuticals (IONS) to Underweight and lowered her price target for the shares to $45 from $52 after PTC Therapeutics (PTCT) reported competing spinal muscular atrophy data. Wang this morning also upgraded PTC to Equal Weight from Underweight.
07/19/18
FBCO
07/19/18
INITIATION
Target $49
FBCO
Outperform
PTC Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse initiated PTC Therapeutics with an Outperform and $49 price target.
06/20/18
WBLR
06/20/18
NO CHANGE
WBLR
Outperform
PTC Therapeutics weakness on Sarepta data overblown, says William Blair
William Blair analyst Raju Prasad believes the weakness in shares of PTC Therapeutics (PTCT) following Sarepta's (SRPT) micro-dystrophin gene therapy data is overblown. In a best-case scenario, the micro-dystrophin gene therapy could be approved in late 2021/early 2022 in the United States and potentially 2022/2023 in Europe, Prasad tells investors in a research note. As such, the analyst believes PTC management's projected five-year annual growth of 15% for Translarna due to increasing penetration in existing countries and potential label expansion remains likely. He still views Translarna and Emflaza revenues through 2022 plus cash on hand worth at least $35 per share, with $12 to $20 per share upside coming from risdiplam's potential in spinal muscular atrophy. Prasad keeps an Outperform rating on PTC Therapeutics.
06/20/18
LEHM
06/20/18
NO CHANGE
LEHM
Barclays upgrades PTC to Equal Weight, downgrades Ionis to Underweight
Barclays analyst Gena Wang upgraded PTC Therapeutics (PTCT) to Equal Weight from Underweight while downgrading Ionis Pharmaceuticals (IONS) to Underweight from Equal Weight. The analyst raised her price target on the former to $40 from $26 and lowered her price target on the latter to $45 from $52. Following PTC's new data in spinal muscular atrophy data, the analyst believes its risdiplam has "disruptive potential" to Ionis and Biogen's (BIIB) Spinraza.
RWT Redwood Trust
$16.64

0.135 (0.82%)

12/07/17
KBWI
12/07/17
UPGRADE
KBWI
Outperform
Redwood Trust upgraded to Outperform from Market Perform at Keefe Bruyette
AEP American Electric
$70.65

0.41 (0.58%)

02/20/18
GUGG
02/20/18
UPGRADE
GUGG
Neutral
American Electric upgraded to Neutral from Sell at Guggenheim
06/18/18
MSCO
06/18/18
NO CHANGE
MSCO
Overweight
Utilities sector upgraded to Overweight at Morgan Stanley
Morgan Stanley equity strategist Michael Wilson noted that year-to-date performance across assets shows large divergences in performance across the risk spectrum, arguing that it is "probably not too early" to start shifting out of some of the extreme cyclicals and picking up more defensively oriented names given the "ever tightening" financial conditions. He upgraded the Utilities sector to Overweight, citing expectations of peak 10 Year Treasury yields and improving relative earnings breadth. The firm has individual Overweight ratings on American Electric (AEP), FirstEnergy (FE), NextEra Energy (NEE), NextEra Energy Partners (NEP), PG&E (PCG), PSEG (PEG) and Xcel Energy (XEL).
07/10/18
LEHM
07/10/18
INITIATION
Target $81
LEHM
Overweight
American Electric initiated with an Overweight at Barclays
Barclays analyst Eric Beaumont started American Electric Power Company with an Overweight rating and $81 price target.
07/19/18
GSCO
07/19/18
UPGRADE
GSCO
Buy
American Electric upgraded to Buy from Neutral at Goldman Sachs
WEC WEC Energy
$65.23

0.51 (0.79%)

07/10/18
LEHM
07/10/18
INITIATION
Target $71
LEHM
Equal Weight
WEC Energy initiated with an Equal Weight at Barclays
Barclays analyst Eric Beaumont started WEC Energy with an Equal Weight rating and $71 price target.
05/23/18
BOFA
05/23/18
UPGRADE
Target $65
BOFA
Buy
WEC Energy upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith upgraded WEC Energy and trimmed its price target to $65 from $67 ahead of a capex acceleration into the EEI conference this fall and a potential delay in its next Wisconsin rate case. The analyst said WEC is increasing its gas capex mix, which should add to incremental opportunities, driven by FoxConn facility, wind, and solar & electric distribution capex.
07/19/18
GSCO
07/19/18
UPGRADE
GSCO
Neutral
WEC Energy upgraded to Neutral from Sell at Goldman Sachs
04/13/18
SBSH
04/13/18
INITIATION
Target $61
SBSH
Neutral
WEC Energy initiated with a Neutral at Citi
Citi analyst Praful Mehta started WEC Energy with a Neutral rating and $61 price target. Without sustained positive regulatory outcomes, the company's credit could trail below 16% post 2019 and push management to take corrective measures, the analyst tells investors in a cesarean note.
SKX Skechers
$33.24

0.61 (1.87%)

06/21/18
UBSW
06/21/18
INITIATION
Target $42
UBSW
Buy
Skechers initiated with a Buy at UBS
UBS analyst Jay Sole started Skechers with a Buy rating and $42 price target.
07/12/18
BUCK
07/12/18
NO CHANGE
Target $42
BUCK
Buy
Buckingham checks suggest healthy demand for Skechers
Buckingham analyst Eric Tracy reiterates a Buy rating and $42 price target for Skechers following positive industry checks and into next week's Q2 results. His checks/discussions with recent industry contacts suggest demand remains healthy/product pipeline evolving nicely, supportive of 2H top line reacceleration, in his view. Tracy believes investments likely mute FY18 EPS upside, with greater opportunities for improved leverage in FY19.
04/20/18
04/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) downgraded to Neutral from Buy at BofA/Merrill and to Hold from Buy at Deutsche Bank aw well as Argus. 2. Philip Morris (PM) downgraded to Buy from Conviction Buy at Goldman Sachs and to Underperform from Neutral at BofA/Merrill. 3. DHT Holdings (DHT) downgraded to Neutral from Overweight at JPMorgan with analyst Noah Parquette saying he has become more constructive on a crude tanker recovery in 2019 but cites relative valuation for the downgrade on DHT. 4. Skechers (SKX) downgraded to Neutral from Outperform at Wedbush with analyst Christopher Svezia citing the company's first quarter results. 5. Tyson Foods (TSN) downgraded to Hold from Buy at Vertical Group. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/20/18
SUSQ
04/20/18
NO CHANGE
Target $40
SUSQ
Positive
Skechers price target lowered to $40 from $52 at Susquehanna
Susquehanna analyst Sam Poser lowered his price target on Skechers to $40 from $52 following Q1 results. He noted the company delivered a slight beat driven by revenues and gross margins but offset by SG&A. He said he would buy the shares on the recent pullback, citing strong demand for its brand. Poser reiterated his Positive rating on Skechers shares.
FTD FTD Companies
$4.52

0.06 (1.35%)

05/09/18
DADA
05/09/18
NO CHANGE
Target $5.25
DADA
Neutral
FTD Companies price target raised to $5.25 from $3.50 at DA Davidson
DA Davidson analyst Linda Bolton Weiser raised her price target on FTD Companies to $5.25 and kept her Neutral rating after its Q1 results. Weiser notes that while the company beat consensus on revenues and maintained its FY18 outlook, costs were also higher and EBITDA missed expectations. The analyst adds however that the issues with Q4 earnings revolving around a poorly executed Valentine's Day promotion have been resolved, and with about a third of the ordering for Mother's Day completed, the outcome is expected to improve.
11/09/17
CHLM
11/09/17
NO CHANGE
Target $10
CHLM
Hold
FTD Companies price target lowered to $10 from $18 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman lowered his price target for FTD Companies to $10 from $18, citing lower Q3 results on continued revenue headwinds. The analyst reiterates a Hold rating on the shares.
11/15/17
DADA
11/15/17
NO CHANGE
Target $8
DADA
Neutral
FTD Companies price target lowered to $8 from $17 at DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target on FTD Companies to $8 and kept her Neutral rating following last week's Q3 results, noting accelerating sales decline due in part to hurricane impacts and the holiday timing shift to Q4 of last year. The analyst's lowered price target is attributed to the uncertainty regarding the timing of return to sales growth as investors await a 5-year strategic turnaround plan from the new CEO John Walden early next year.
03/09/18
DADA
03/09/18
NO CHANGE
Target $4.25
DADA
Neutral
FTD Companies had 'poor Valentine's Day execution', says DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target on FTD Cmpanies to $4.25 from $6.50 after the company's Q1 warning that was attributed to poor execution in marketing strategies around Valentine's Day. The analyst adds that in order to reach the company's revenue outlook for the entire FY18, she also had to bump up her forecasts for Q2-Q4, suggesting that the company's low end of FY18 EBITDA guidance of $52M may prove to be a stretch. Weiser keeps her Neutral rating on FTD Companies.
ZYNE Zynerba
$10.40

0.24 (2.36%)

02/01/18
02/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Epizyme (EPZM) initiated with a Buy at Roth Capital. 2. Take-Two (TTWO) initiated with an Overweight at Morgan Stanley. 3. AMERI Holdings (AMRH) initiated with an Outperform at Northland. 4. Simply Good Foods (SMPl) initiated with a Buy at SunTrust. 5. Zynerba (ZYNE) assumed with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/16/18
HCWC
04/16/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba shares remain undervalued, says H.C. Wainwright
Zynerba Pharmaceuticals and its pipeline "could gain incremental visibility and appreciation with immediate and near-term catalysts," H.C. Wainwright analyst Oren Livnat tells investors in a research note. The analyst continues to believe the company is undervalued. His $23 price target is based exclusively on 35% probability of success of ZYN002 - synthetic cannabidiol transdermal gel - in Fragile X syndrome. The analyst does not yet include any credit for potential ZYN002 epilepsy indications. Investors may soon begin to give more credit to this indication with two catalysts this month, Livnat writes. He reiterates a Buy rating on Zynerba.
02/01/18
HCWC
02/01/18
INITIATION
Target $23
HCWC
Buy
Zynerba assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat assumed coverage of Zynerba Pharmaceuticals with a Buy rating and $23 price target. The company could have the first ever Fragile X syndrome treatment approved by end-2020, the analyst contends.
07/05/18
HCWC
07/05/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba failed program not material negative, says H.C. Wainwright
Zynerba Pharmaceuticals this morning announced it is discontinuing development of its transdermal THC pro-drug patch ZYN001 after a Phase 1 study in healthy subjects failed to deliver the targeted potential therapeutic blood levels. This development is not a material negative, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The analyst says he never included ZYN001 for Tourette's or any other indication in his estimates or valuation. He notes that his valuation is entirely based on orphan designated ZYN002 transdermal cannabidiol gel for Fragile X syndrome, entering Phase 3 shortly, "with upside optionality from ongoing work in refractory and rare epilepsies." Livnat views the early-stage ZYN001 termination "as a sign of responsible drug development" and keeps a Buy rating on Zynerba with a $23 price target. The stock in afternoon trading is down 54c to $9.07.

TODAY'S FREE FLY STORIES

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
08/20/18
08/20
09:18
08/20/18
09:18
Options
Overnight activity included 128 trades in SPX and 19 trades in VIX »

128 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PINC

Premier

$38.38

0.24 (0.63%)

09:15
08/20/18
08/20
09:15
08/20/18
09:15
Hot Stocks
Premier to provide operational transformation consulting to UofL Hospital, ULP »

Premier has expanded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 05

    Sep

  • 14

    Sep

OPTT

Ocean Power

$0.76

0.0501 (7.06%)

, E

Eni SpA

$36.28

0.12 (0.33%)

09:14
08/20/18
08/20
09:14
08/20/18
09:14
Hot Stocks
Ocean Power ships PB3 PowerBuoy to Eni SpA »

Ocean Power (OPTT)…

OPTT

Ocean Power

$0.76

0.0501 (7.06%)

E

Eni SpA

$36.28

0.12 (0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SODA

SodaStream

$129.89

1.12 (0.87%)

, PEP

PepsiCo

$114.98

0.7 (0.61%)

09:14
08/20/18
08/20
09:14
08/20/18
09:14
Hot Stocks
Fly Intel: Pre-market Movers »

HIGHER: SodaStream…

SODA

SodaStream

$129.89

1.12 (0.87%)

PEP

PepsiCo

$114.98

0.7 (0.61%)

TSLA

Tesla

$305.33

-30.13 (-8.98%)

MIXT

MiX Telematics

$15.09

-0.17 (-1.11%)

NKE

Nike

$79.73

-0.32 (-0.40%)

BBOX

Black Box

$1.64

0.09 (5.81%)

LCI

Lannett

$13.50

-0.25 (-1.82%)

INFY

Infosys

$21.09

0.095 (0.45%)

STZ

Constellation Brands, also tag STZ.B

$203.90

1.47 (0.73%)

NWS

News Corp

$14.40

0.1 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

  • 12

    Sep

  • 02

    Oct

  • 28

    Oct

  • 29

    Oct

AKAO

Achaogen

$5.91

0.21 (3.68%)

09:13
08/20/18
08/20
09:13
08/20/18
09:13
Recommendations
Achaogen analyst commentary  »

Achaogen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Aug

  • 31

    Aug

TSLA

Tesla

$305.33

-30.13 (-8.98%)

09:13
08/20/18
08/20
09:13
08/20/18
09:13
Recommendations
Tesla analyst commentary  »

Tesla price target cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

RADA

RADA Electronic

$2.52

-0.02 (-0.79%)

09:11
08/20/18
08/20
09:11
08/20/18
09:11
Hot Stocks
RADA Electronic's MHR to be delivered to the British Army »

RADA Electronic announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:10
08/20/18
08/20
09:10
08/20/18
09:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

LTBR

Lightbridge

$0.87

0.004 (0.46%)

09:08
08/20/18
08/20
09:08
08/20/18
09:08
Hot Stocks
Lightbridge CFO Linda Zwobota to retire, Larry Goldman to succeed »

Lightbridge announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$217.65

4.16 (1.95%)

09:05
08/20/18
08/20
09:05
08/20/18
09:05
Downgrade
Apple rating change  »

Apple downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:05
08/20/18
08/20
09:05
08/20/18
09:05
General news
Treasury Action: yields have extended early declines »

Treasury Action: yields…

JCP

J.C. Penney

$1.79

0.025 (1.42%)

09:04
08/20/18
08/20
09:04
08/20/18
09:04
Hot Stocks
J.C. Penney unveils new, exclusive big & tall brand with Shaquille O'Neal »

Building on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICHR

Ichor Holdings

$21.32

-0.57 (-2.60%)

09:04
08/20/18
08/20
09:04
08/20/18
09:04
Hot Stocks
Ichor Holdings announces $50M increase to share repurchase program »

Ichor Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

IVAC

Intevac

$5.03

0.225 (4.69%)

09:03
08/20/18
08/20
09:03
08/20/18
09:03
Hot Stocks
Intevac announces $10M expansion of existing $30M share repurchase program »

Intevac announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BXP

Boston Properties

$132.14

0.5 (0.38%)

09:02
08/20/18
08/20
09:02
08/20/18
09:02
Recommendations
Boston Properties analyst commentary  »

Boston Properties price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RICK

RCI Hospitality

$32.61

0.36 (1.12%)

09:02
08/20/18
08/20
09:02
08/20/18
09:02
Hot Stocks
RCI Hospitality to acquire Blush Gentlemen's Club & Sports Bar for $15M »

RCI Hospitality announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$95.23

-1.47 (-1.52%)

08:58
08/20/18
08/20
08:58
08/20/18
08:58
Hot Stocks
Guidewire contributes to report on cyber insurance market »

Guidewire Software helped…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 12

    Sep

AAPL

Apple

$217.65

4.16 (1.95%)

, TSLA

Tesla

$305.33

-30.13 (-8.98%)

08:55
08/20/18
08/20
08:55
08/20/18
08:55
Options
Notable open interest changes for August 20th »

Friday's total…

AAPL

Apple

$217.65

4.16 (1.95%)

TSLA

Tesla

$305.33

-30.13 (-8.98%)

BABA

Alibaba

$172.76

0.78 (0.45%)

FB

Facebook

$173.78

-0.98 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 23

    Aug

  • 06

    Sep

  • 10

    Sep

  • 18

    Sep

  • 29

    Oct

PAY

Verifone

$23.04

0.01 (0.04%)

08:54
08/20/18
08/20
08:54
08/20/18
08:54
Hot Stocks
Breaking Hot Stocks news story on Verifone »

Verifone trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQDA

Liquidia Technologies

$14.30

-0.12 (-0.83%)

08:52
08/20/18
08/20
08:52
08/20/18
08:52
Initiation
Liquidia Technologies initiated  »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$9.56

0.04 (0.42%)

08:51
08/20/18
08/20
08:51
08/20/18
08:51
Recommendations
Ford analyst commentary  »

Ford risks high, but so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Aug

TNDM

TNDM

, DXCM

DexCom

$130.93

2.61 (2.03%)

08:51
08/20/18
08/20
08:51
08/20/18
08:51
Recommendations
TNDM, DexCom analyst commentary  »

Tandem Diabetes price…

TNDM

TNDM

DXCM

DexCom

$130.93

2.61 (2.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 12

    Sep

  • 13

    Sep

  • 20

    Sep

  • 21

    Sep

08:50
08/20/18
08/20
08:50
08/20/18
08:50
General news
Fedspeak from Atlanta Fed dove Bostic »

Fedspeak from Atlanta Fed…

VERI

Veritone

$11.41

0.11 (0.97%)

08:49
08/20/18
08/20
08:49
08/20/18
08:49
Conference/Events
Veritone to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

VMC

Vulcan Materials

$110.31

0.46 (0.42%)

08:47
08/20/18
08/20
08:47
08/20/18
08:47
Recommendations
Vulcan Materials analyst commentary  »

Vulcan Materials price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.